Azithromycin is an antibiotic drug with additional properties, including immunomodulatory activity (Vrančić et al., 2012) and an ability to stimulate gastro‐duodenal motility (Sifrim et al., 1994; Chini et al., 2012).Furthermore, azithromycin is increasingly suggested as a potential treatment of upper gastrointestinal (GI) motility disorders … Epub 2004 Dec 8.Araki N, Yanagihara K, Morinaga Y, Yamada K, Nakamura S, Yamada Y, Kohno S, Kamihira S.Eur J Pharmacol. The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation.
Clipboard, Search History, and several other advanced features are temporarily unavailable. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.Available data from published observational studies, case series, and case reports over several decades do not suggest an increased risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with azithromycin use in pregnant women. The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance with clinical response.The infusate concentration and rate of infusion for azithromycin for injection should be either 1 mg/mL over 3 hr or 2 mg/mL over 1 hr. COVID-19 is an emerging, rapidly evolving situation. Azithromycin administered during the period of organogenesis did not cause fetal malformations in rats and mice at oral doses up to 200 mg/kg/day (moderately maternally toxic). The pharmacokinetic profiles of azithromycin given as a single-dose regimen (2.0-g extended-release microspheres) were characterized in serum and white blood cells (WBC) and compared with those of a 3-day regimen (a 500-mg immediate-release tablet once daily; total dose, 1.5 g) in an open-label, randomized, parallel-group study of 24 healthy adult subjects. By continuing to browse
Son métabolisme hépatique, par un système n'impliquant pas le cytochrome P450, minimise le risque d'interactions médicamenteuses.En comparaison avec les autres macrolides, les caractéristiques pharmacocinétiques et pharmacodynamiques de lazithromycine offrent un potentiel accru d'efficacité et de sécurité. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. Ureaplasma spp.   FDA-approved labeling recommends IV therapy for at least 2 days then step-down to oral therapy to complete a 7- to 10-day treatment course.
If particulate matter is evident in reconstituted fluids, the drug solution should be discarded.To provide azithromycin over a concentration range of 1 mg/mL to 2 mg/mL, transfer 5 mL of the 100 mg/mL azithromycin solution into the appropriate amount of any of the diluents listed below:5% Dextrose in 1/2 Normal Saline (0.45% sodium chloride) with 20 mEq KCl5% Dextrose in 1/3 Normal Saline (0.3% sodium chloride)5% Dextrose in 1/2 Normal Saline (0.45% sodium chloride)Other intravenous substances, additives, or medications should not be added to azithromycin for injection, or infused simultaneously through the same intravenous line.When diluted according to the instructions (1 mg/mL to 2 mg/mL), azithromycin for injection is stable for 24 hr at or below room temperature 30°C (86°F), or for 7 days if stored under refrigeration 5°C (41°F).Azithromycin for injection, USP is supplied as white lyophilized cake or powder in a 10 mL vial equivalent to 500 mg of azithromycin for intravenous administration.Azithromycin is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drugs.Azithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome, and toxic epidermal necrolysis have been reported in patients on azithromycin therapy.